Who says no to a $10,000 watch? Are there second acts in Big Pharma? And what’s it like to climb Mount Everest?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation on biotech’s little-discussed war for talent, which is lining the pockets of the few people who actually know how to make next-generation treatments. Then we talk to Dr. Gary Nabel, chief scientific officer at Sanofi, about how the company plans to make up lost ground in the lucrative field of oncology. Finally, biotech journalist Luke Timmerman joins us to detail his trip to the top of Everest and we run through a lightning round on Hong Kong IPOs, unicorn staffing problems, and a pioneering FDA decision.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy